Identification, characterization, and anti-inflammatory activity of a lipocalin-like protein cloned from .

This study investigated the anti-inflammatory effects of OJlipo1, a lipocalin-like protein derived from . Through cloning and expressing OJlipo1 in , and subsequent rigorous characterization including amino acid analysis and mass spectrometry, its potential against inflammation was evaluated. Studies on lipopolysaccharide-stimulated RAW 264.7 cells highlighted its capability to suppress nitric oxide synthase and cyclooxygenase-2 expression, as well as its interference with nuclear factor kappa B and mitogen-activated protein kinase pathways, which are essential for toll-like receptor 4 (TLR4) signaling. Utilizing TAK242, a TLR4 pathway inhibitor, reinforced OJlipo1's specific targeting mechanism. These findings underscore OJlipo1's significant anti-inflammatory potential, aligning with the traditional uses of , and suggest new therapeutic avenues, especially for diseases associated with TLR4 dysregulation. This validates the traditional application of in inflammation and positions OJlipo1 as a promising therapeutic candidate, enriching our understanding of its molecular underpinnings and therapeutic prospects.